Why the study?
Do angiotensin II receptor blockers improve cardiovascular outcomes in patients across the cardiovascular continuum?
Do angiotensin II receptor blockers improve cardiovascular outcomes in patients across the cardiovascular continuum?
ARBs provide cardiovascular benefits across a wide spectrum of patients, from those with risk factors to those with established heart failure.
ARBs may warrant consideration across the CV continuum; leaves open comparative effectiveness versus contemporary therapies in updated trials.
Activation of the renin-angiotensin system plays a major role in cardiovascular morbidity and mortality. Recently, angiotensin II receptor blockers (ARBs) have been the subject of a number of large clinical cardiovascular outcome trials, indicating beneficial effects of ARBs with more than 384,000 patient-years of data in different cardiovascular diseases along the cardiovascular continuum, from patients with risk factors, through high cardiovascular risk, to patients with heart failure. This article reviews the implications of these trials for the optimal management of cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Baumhäkel et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: